Before the blood-banking era, a hemorrhage in a boy with hemophilia often was treated with a direct whole-blood transfusion from a parent. The amount of the deficient clotting factor transferred, and thus the hemostatic effect, was necessarily small, but so was the risk of exposure to an infection not already shared by donor and recipient. In this issue of The Journal, McLeod and Scott1 describe their return to a parent or other single designated donor to provide the advantage of limited infection risk, coupled now with the hemostatic efficacy of cryoprecipitate prepared from large volumes of plasma obtained by plasmapheresis.
The triumphs and disasters of modern hemophilia treatment are well known. Excellent control of bleeding has been possible through the use of cryoprecipitate, usually prepared as a by-product of whole-blood donation from multiple community donors, and lyophilized clotting-factor concentrate, prepared primarily from the pooled plasma of paid plasmapheresis donors
Kasper CK. Cryoprecipitate: All in the Family?. JAMA. 1984;252(19):2755–2756. doi:10.1001/jama.1984.03350190057023